10 Best Vaccine Stocks to Buy According to Hedge Funds

6. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 55

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors. The company has grown its revenue by 17.77% over the last 5 years.

AstraZeneca PLC (NASDAQ:AZN) is strengthening its portfolio of FDA-approved drugs. In January, it obtained FDA approval for Dato DXd, a treatment for advanced-stage breast cancer. AstraZeneca PLC (NASDAQ:AZN) estimates that this treatment will generate annual sales of $5 billion. It also plans to release seven high-value drugs in the market in 2025.

The company reported a $1.5 billion increase in net cash flow from operating activities in 2024. It paid off approximately $7 billion in debt and grew its pipeline through strategic acquisitions, such as Fusion, Icosavax, and Amolyt. AstraZeneca PLC (NASDAQ:AZN) expects overall sales to grow at a high single-digital rate in 2025 and core EPS to rise by a low double-digit percentage. The company takes the sixth spot on our list of the 10 best vaccine stocks to buy according to hedge funds.